New-generation antidepressants, suicide and depressed adolescents: How should clinicians respond to changing evidence?

Australian and New Zealand Journal of Psychiatry

Volumn 42, Issue 6, 2008, Pages 456-466

  Dudley, Michael ^a   Hadzi Pavlovic, Dusan ^b   Andrews, Doug ^b   Perich, Tania ^c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c BLACK DOG INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; NEW GENERATION ANTIDEPRESSANT AGENT; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ANXIETY; ARTICLE; ASTHENIA; AUTOMUTILATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; INSOMNIA; LOW DRUG DOSE; MEDICAL DECISION MAKING; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SWEATING; SYSTEMATIC REVIEW; TREMOR; WITHDRAWAL SYNDROME;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHILD; DEPRESSIVE DISORDER; HUMANS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SUICIDE; TREATMENT OUTCOME;

EID: 45949103111     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670802050538     Document Type: Article

References (107)

1. Hammad, T., Laughren, T. and Racoosin, J. (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry, 63, pp. 332-339.
2. Martinez, C., Rietbrock, S. and Wise, L. (2005) Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: Nested case-control study. BMJ, 330, p. 389.
3. Hammad, T. Results of the analysis of suicidality in pediatric trials of newer antidepressants
4. Isacsson, G., Holmgren, P. and Ahlner, J. (2005) Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: A controlled forensic database study of 14857 suicides. Acta Psychiatr Scand, 111, pp. 286-290.
5. Jick, H., Kaye, JA and Jick, SS. (2004) Antidepressants and the risk of suicidal behaviors. JAMA, 292, pp. 338-343.
6. Leon, A., Marzuk, P., Tardiff, K., Bucciarelli, A., Markham, KP and Galea, S. (1993) Paroxetine, other drugs and youth suicide in New York City, through 1998. J Clin Psychiatry; 65, 2004, pp. 915-918.
7. Moskos, M., Olson, L., Halbern, S., Keller, T. and Gray, D. (2005) Utah youth suicide study: Psychological autopsy. Suicide Life Threat Behav, 35, pp. 536-546.
8. Søndergård, L., Kvist, K., Andersen, P. and Kessing, LL. (2006) Do antidepressants precipitate youth suicide: A national pharmacoepidemiological study. Eur J Child Adolesc Psychiatr, 15, pp. 232-240.
9. Gibbons, RD, Hur, K., Bhaumik, DK and Mann, JJ. (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry, 163, pp. 1898-1904.
10. Ludwig, J. and Marcotte, DE. (2005) Anti-depressants, suicide, and drug regulation. J Policy Anal Manage, 24, pp. 249-272.
11. Simon, G. (2006) The antidepressant quandary-considering suicide risk when treating adolescent depression. N Engl J Med, 355, pp. 2722-2723.
12. Hall, WD and Lucke, J. (2006) How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?. Aust N Z J Psychiatry, 40, pp. 941-950.
13. Licinio, J. and Wong, M-L. (2005) Depression, antidepressants and suicidality: A critical re-appraisal. Nat Rev Drug Discov, 4, pp. 165-171.
14. Gunnell, D., Saperia, J. and Ashby, D. (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ, 330, p. 385.
15. Fergusson, D., Doucette, S. and Glass, CK (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ, 330, p. 396.
16. Goldney, RD. (2006) Suicide and antidepressants: What is the evidence?. Aust N Z J Psychiatry, 40, pp. 381-385.
17. Jureidini, JN, Doecke, CJ, Mansfield, PR, Haby, MM, Menkes, DB and Tonkin, AL. (2004) Efficacy and safety of antidepressants for children and adolescents. BMJ, 328, pp. 879-883.
18. Bridge, JA, Iyengar, S. and Salary, CB (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA, 297, pp. 1683-1696.
19. Kratochvil, C., Emslie, G. and Silva, S. (2006) Acute time to response in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry, 45, pp. 1412-1418.
20. Mosholder, AD and Willy, M. (2006) Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: A meta-analysis. J Child Adolesc Psychopharmacol, 16, pp. 25-32.
21. Kaizar, EE, Greenhouse, JB, Seltman, H. and Kelleher, K. (2006) Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials, 3, pp. 73-98.
22. Klein, D. (2006) The flawed basis for FDA post-marketing safety decisions: The example of antidepressants and children. Neuropsychopharmacology, 31, pp. 689-699.
23. Mann, J., Emslie, G. and Baldessarini, R. (2006) ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology, 31, pp. 473-492.
24. Cheung, AH, Emslie, GJ and Mayes, TL. (2005) Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry, 46, pp. 735-754.
25. Moreno, C., Arango, C., Parellada, M., Shaffer, D. and Bird, H. (2007) Antidepressants in child and adolescent depression: Where are the bugs?. Acta Psychiatr Scand, 115, pp. 184-195.
26. Cohen, D. (2007) Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?. Psychother Psychosom, 76, pp. 5-17.
27. Whittington, CJ, Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A. and Boddington, E. (2004) Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363, pp. 1341-1345.
28. Hetrick, S., McKenzie, J., Sindahl, P. and Proctor, M. (2007) Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev
29. Jaffee, S., Moffitt, T., Caspi, A., Fombonne, E., Poulton, R. and Martin, J. (2002) Differences in early childhood risk factors for juvenile-onset and adult-onset depression. Arch Gen Psychiatry, 59, pp. 215-222.
30. Sawyer, MG, Arney, FM and Baghurst, PA. (2001) The mental health of young people in Australia: Key findings from the child and adolescent component of the national survey of mental health and well-being. Aust N Z J Psychiatry, 35, pp. 806-814.
31. Kessler, RC and Walters, EE. (1998) Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety, 7, pp. 3-14.
32. Beautrais, A. (2000) Risk factors for suicide and attempted suicide among young people. Aust N Z J Psychiatry, 34, pp. 420-436.
33. Rey, JM, Sawyer, MG, Clark, JJ and Baghurst, PA. (2001) Depression among Australian adolescents. Med J Aust, 175, pp. 19-23.
34. Vitiello, B., Zuveka, SH and Norquist, GS. (2006) National estimates of antidepressant medication use among U.S. children, 1997-2002. J Am Acad Child Adolesc Psychiatry, 45, pp. 271-279.
35. Gibbons, RD, Brown, CH and Hur, K. (2007) Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry, 164, pp. 1356-1363.
36. American Academy of Child and Adolescent Psychiatry (1998) Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry, 37, pp. 63S-83S.
37. Henry, JA, Alexander, CA and Sener, EK. (1995) Relative mortality from overdose of antidepressants. BMJ, 310, pp. 221-224.
38. Kaufman, J., Martin, A., King, RA and Charney, D. (2001) Are child-, adolescent-, and adult-onset depression one and the same disorder?. Biol Psychiatry, 49, pp. 980-1001.
39. Hazell, P., O'Connell, D., Heathcote, D. and Henry, D. (1995) Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. BMJ, 310, pp. 897-901.
40. Hazell, P., O'Connell, D., Heathcote, D. and Henry, D. (2002) Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev
41. Emslie, GJ, Heiligenstein, JH and Wagner, KD (2002) Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry, 41, pp. 1205-1215.
42. Emslie, GJ, Rush, AJ and Weinberg, WA (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry, 54, pp. 1031-1037.
43. Wagner, KD, Ambrosini, P. and Rynn, M. (2003) Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA, 290, pp. 1033-1041.
44. Keller, M., Ryan, N. and Strober, M. (2001) Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry, 40, pp. 762-772.
45. Wagner, KD, Robb, AS, Findling, RL, Jin, J., Gutierrez, MM and Heydorn, WE. (2004) A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry, 161, pp. 1079-1083.
46. Kirsch, D. and Antonuccio, D. (2004) FDA testimony of Dr David Kirsch and Dr David Antonuccio on the efficacy of antidepressants in children, New York
47. Moncrieff, J. and Kirsch, I. (2005) Efficacy of antidepressants in adults. BMJ, 331, pp. 155-157.
48. Treatment for Adolescents With Depression Study (TADS) Team (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 292, pp. 807-820.
49. Timimi, S. (2004) Rethinking childhood depression. BMJ, 329, pp. 1394-1396.
50. Raz, A. (2006) Perspectives on the efficacy of antidepressants for child and adolescent depression. PLoS Med, 3, p. e9.
51. March, JS. (2005) Authors of TADS study reply to letter raising concerns. BMJ, 330, pp. 730-731.
52. Curry, J., Rodhe, P. and Simons, A. (2006) Predictors and moderators of acute outcome in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry, 45, pp. 1427-1438.
53. Goodyer, I., Dubicka, B. and Wilkinson, P. (2007) Selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ, 335, p. 142.
54. The TADS Team (2007) The Treatment for Adolescents with Depression Study (TADS): Long-term effectiveness and safety outcomes. Arch Gen Psychiatry, 64, pp. 1132-1144.
55. American Academy of Child and Adolescent Psychiatry (AACAP) (2007) Practice parameter for the assessment and treatment of children and adolescents with depressive disorders, Washington, DC
56. March, JS, Klee, BJ and Kremer, CME. (2006) Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Adolesc Psychopharmacol, 16, pp. 91-102.
57. Geller, DA, Biederman, J. and Stewart, SE (2003) Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry, 160, pp. 1919-1928.
58. Seidel, L. and Walkup, JT. (2006) Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders. J Child Adolesc Psychopharmacol, 16, pp. 171-179.
59. Pine, DS, Cohen, P., Gurley, D., Brook, J. and Ma, Y. (1998) The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry, 55, pp. 56-64.
60. Weissman, MM, Wolk, S. and Goldstein, RB (1999) Depressed adolescents grown up. JAMA, 281, pp. 1707-1713.
61. Masand, P., Gupta, S. and Dewan, M. (1991) Suicidal ideation related to fluoxetine treatment. N Engl J Med, 324, p. 420.
62. Rothschild, AJ and Locke, CA. (1991) Re-exposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatry, 52, pp. 491-493.
63. Teicher, MH, Glod, C. and Cole, JO. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry, 142, pp. 207-210.
64. King, R., Riddle, M. and Chappell, P. (1991) Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry, 30, pp. 179-186.
65. Beasley, CM, Dornseif, BE and Bosomworth, JC (1991) Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. BMJ, 303, pp. 685-692.
66. Department of Health and Human Services PHS, Food and Drug Administration (1991) Psychopharmacological Drugs Advisory Committee, Rockville, MD
67. European Medicines Agency (2005) European Medicines Agency finalises review of antidepressants in children and adolescents, London, UK
68. Australian Adverse Drug Reactions Advisory Committee (2004) Use of SSRI antidepressants in children and adolescents, Canberra, ACT
69. Rubino, A., Roskell, N., Tennis, P., Mines, D., Weich, S. and Andrews, E. (2007) Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: Retrospective cohort study. BMJ, 334, p. 242.
70. Mines, D., Hill, D., Yu, H. and Novelli, H. (2005) Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine and citalopram. Pharmacoepidemiol Drug Saf, 14, pp. 367-372.
71. U.S. Department of Health and Human Services (2007) Newer class of antidepressants similar in effectiveness, but side effects differ, Rockville, MD
72. Healy, D. (2003) Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom, 72, pp. 71-80.
73. Breggin, PR. (2004) Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. Int J Risk Saf Med, 16, pp. 31-49.
74. Healy, D. (2006) Did regulators fail over selective serotonin reuptake inhibitors?. BMJ, 333, pp. 92-95.
75. Healy, D., Herxheimer, A. and Menkes, DB. (2006) Antidepressants and violence: Problems at the interface of medicine and law. PLoS Med, 3, p. e372.
76. US Food and Drug Administration Clinical Review (2006) Relationship between antidepressant drugs and suicidality in adults, Rockville
77. Friedman, R. and Leon, A. (2007) Expanding the black box: Depression, antidepressants, and the risk of suicide. N Engl J Med, 356, pp. 2343-2346.
78. Mackay, F., Dunn, N., Martin, R., Pearce, G., Freemantle, S. and Mann, R. (1999) Newer antidepressants: A comparison of tolerability in general practice. Br J Gen Pract, 49, pp. 892-896.
79. Mosholder, AD and Pamer, CA. (2006) Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. J Child Adolesc Psychopharmacol, 16, pp. 33-36.
80. Findling, RL, McNamara, NK and Stansbrey, RJ (2006) The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol, 16, pp. 131-145.
81. Moynihan, R. and Cassels, A. (2005) Selling sickness, Nation Books, New York, NY
82. Bell, G. (2005) The worried well: The depression epidemic and the medicalisation of our sorrows. Q Essay, 18, pp. 1-74.
83. Parker, G. (2005) The worried well: Correspondence. Q Essay, 19, pp. 88-95.
84. Committee of Safety of Medicines (2005) Selective serotonin reuptake inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents, London, UK
85. Shaffer, D. (2005) Depressive disorders and suicide in children and adolescents. Comprehensive textbook of psychiatry, vol II, pp. 3262-3274. Lippincott Williams & Wilkins, Philadelphia, PA
86. Rigioni, GC Drug utilization for selected antidepressants among children & adolescents in the US
87. Leslie, L., Newman, T., Chesney, P. and Perrin, J. (2005) The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics, 116, pp. 195-204.
88. Pfeffer, C. (2007) The FDA advisories and changes in diagnosis and treatment of depression. Am J Psychiatry, 164, pp. 843-846.
89. Wells, KB. (1999) Treatment research at the crossroads. The scientific interface of clinical trials and effectiveness research. Am J Psychiatry., 156, pp. 5-10.
90. Black, N. (1996) Why we need observational studies to evaluate the effectiveness of health research. BMJ, 312, pp. 1215-1218.
91. Simon, GE, Savarino, J., Operskalski, B. and Wang, PS. (2006) Suicide risk during antidepressant treatment. Am J Psychiatry, 163, pp. 41-47.
92. Valuck, RJ, Libby, AM, Sills, MR, Giese, AA and Allen, RR. (2004) Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: A propensity adjusted retrospective cohort study. CNS Drugs, 18, pp. 1119-1132.
93. Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A. and Haukka, J. (2006) Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry, 63, pp. 1358-1367.
94. Mayer-Gross, W., Slater, E. and Roth, M. (1960) Clinical psychiatry, Bailliere, Tindall and Cassell, London, UK
95. Wessely, S. and Kerwin, R. (2004) Suicide risk and the SSRIs. JAMA, 292, pp. 379-381.
96. Martin, A., Young, C., Leckman, JF, Mukonoweshuro, C., Rosenbeck, R. and Leslie, D. (2004) Age effects on antidepressant induced manic conversion. Arch Pediatr Adolesc Med, 158, pp. 773-780.
97. Goldney, R. (2000) The prediction of suicide. The international handbook of suicide and attempted suicide, pp. 585-596. Wiley and Sons, Chichester, UK
98. Royal Australian and New Zealand College of Psychiatrists, Royal College of General Practitioners, and Royal Australasian College of Physicians (2005) Clinical guidelines on the use of antidepressant medications for children and adolescents. Aust Fam Physician, 34, pp. 777-778.
99. Hodes, M. and Garralda, E. (2007) NICE guidelines on depression in children and young people: Not always following the evidence. Psychiatr Bull R Coll Psychiatr, 31, pp. 361-362.
100. Watanabe, N., Hunot, V., Omori, IM, Churchill, R. and Furukawa, TA. (2007) Psychotherapy for depression among children and adolescents: A systematic review. Acta Psychiatr Scand, 116, pp. 84-95.
101. Kennedy, SH, Konarski, JZ and Segal, ZV (2007) Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry, 164, pp. 778-788.
102. Boylan, K., Romero, S. and Birmaher, B. (2007) Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology, 191, pp. 27-38.
103. (2003) Therapeutic Guidelines: Psychotropic, Therapeutic Guidelines Limited, Melbourne
104. Heiligenstein, JH, Hoog, SL and Wagner, KD (2006) Fluoxetine 60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20mg: A pilot study. J Child Adolesc Psychopharmacol, 16, pp. 207-217.
105. Emslie, GJ, Hughes, CW, Crismon, ML, Lopez, M., Toprac, MG and Boemer, C. (2004) A feasibility study of the childhood depression medication algorithm: The Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry, 43, pp. 519-527.
106. Walter, G. and Rey, J. (2003) Has the practice and outcome of ECT among adolescents changed? Findings from a whole population study. J ECT, 19, pp. 88-92.
107. Emslie, GJ, Heiligenstein, JH and Hoog, SL (2004) Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry, 43, pp. 1397-1405.